WuXi AppTec Co., Ltd. Class H (2359) AI Stock Analysis

• Market Cap: HK$307.02B
• Dividend Yield: 1.84%
• Average Volume (3M): 6.08M
• Price to Earnings (P/E): 21.9
• Beta (1Y): 1.60
• Revenue Growth: 11.55%
• EPS Growth: 64.46%
• Country: HK
• Employees: 39,414
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): 1.35
• Shares Outstanding: 510,476,900
• 10 Day Avg. Volume: 5,559,442
• 30 Day Avg. Volume: 6,076,831
• PEG Ratio: 13.17
• Price to Book (P/B): 2.62
• Price to Sales (P/S): 3.92
• P/FCF Ratio: 18.29
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: HK$146.05
• Price Target Upside: 28.57% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): 6.11
• Revenue Forecast (FY): HK$56.82B

• Rating: 69 Neutral
• Price Target: HK$124.00 ▲(9.15% Upside)
• Action: Downgraded Date: 12/18/25
• Date: Action: Downgraded 12/18/25

WuXi AppTec's strong financial performance is the most significant factor, showcasing robust revenue growth and profitability. However, the technical analysis indicates a bearish trend, which tempers the overall score. The valuation is reasonable, providing some support to the stock's attractiveness.

Positive Factors

Margin Sustainability

High gross and net margins indicate durable operational efficiency across WuXi AppTec’s integrated CRAMS platform. Sustained margins support reinvestment in capacity and R&D services, underpinning long‑term profitability even as revenue scales.

Conservative Capital Structure

Very low leverage and a high equity ratio provide financial resilience, lower funding costs, and flexibility to invest in capacity or M&A. This conservative balance sheet supports multi‑year growth initiatives and buffers cyclicality in client demand.

Cash Generation Ability

Consistent free cash flow and positive cash conversion ratios demonstrate the firm’s ability to monetize services and fund operations. Persistent cash generation sustains capex, working capital needs and client service expansion over the medium term.

Negative Factors

Cash Conversion Lag

OCF materially below reported net income suggests earnings aren’t fully converting to cash, likely due to working capital or timing. Over months this can constrain discretionary spend, slow capacity buildouts, or pressure dividend and investment plans.

Modest Free Cash Flow Growth

Free cash flow growth is positive but modest relative to business scale. Slow FCF expansion may limit the pace of capital-intensive capacity additions and reduce flexibility to pursue larger strategic investments without external funding.

Exposure to R&D Spending Cycles

Revenue is tied to client R&D and outsourcing budgets. Structural fluctuations in pharma/biotech R&D allocations can cause multi‑quarter swings in project demand, making top‑line visibility and utilization rates sensitive to industry cycles.

WuXi AppTec Co., Ltd. Class H Business Overview & Revenue Model

Company Description

WuXi AppTec Co., Ltd., an investment holding company, provides research, development, and manufacturing services to discover, develop, and manufacture small molecule drugs, and cell and gene therapies in the People's Republic of China, rest of Asia, the United States, Europe, and internationally. The company operates through six segments: WuXi Chemistry, WuXi Testing, WuXi Biology, WuXi ATU, WuXi DDSU, and Others. It offers contract research, development, and manufacturing organization services for new drug development from discovery to commercial covering various categories for various synthetic molecular modalities, including small molecules, oligonucleotides, peptides, and complex conjugates; and biology services and solutions that support stand-alone and integrated projects from target discovery to candidate selection and into the clinic. The company also provides seamless drug and medical device testing services from preclinical testing to clinical trials; an integrated end-to-end solution to accelerate time to market for cell and gene therapies; drug discovery services to pharmaceutical and biotech customers; and clinical research services. WuXi AppTec Co., Ltd. was founded in 2000 and is headquartered in Shanghai, the People's Republic of China.

How the Company Makes Money

WuXi AppTec generates revenue through multiple streams, primarily by offering contract research and manufacturing services (CRAMS) to pharmaceutical and biotechnology companies. These services include drug discovery, preclinical and clinical development, and commercial manufacturing. The company typically charges fees based on the scope and complexity of the services provided. Significant partnerships with major pharmaceutical firms enhance its earnings by securing long-term contracts and collaborations, which also help diversify its client base. Additionally, WuXi AppTec may earn revenue through licensing agreements and collaborations in drug development, further strengthening its financial position.

WuXi AppTec Co., Ltd. Class H Financial Statement Overview

Summary

WuXi AppTec demonstrates strong financial health with impressive revenue growth, profitability, and cash flow generation. The company maintains a conservative leverage position and effectively utilizes equity to drive returns. Continuous monitoring of growth sustainability and cash flow conversion is essential.

Income Statement

WuXi AppTec has demonstrated strong revenue growth with a 6.31% increase in TTM, alongside robust profitability metrics. The gross profit margin of 45.66% and net profit margin of 33.20% indicate efficient cost management and strong bottom-line performance. EBIT and EBITDA margins are also impressive at 39.72% and 44.73%, respectively, showcasing operational efficiency.

Balance Sheet

The company maintains a healthy balance sheet with a low debt-to-equity ratio of 0.12, indicating conservative leverage. Return on equity is strong at 23.34%, reflecting effective use of shareholder funds. The equity ratio of 74.98% suggests a solid capital structure with a high proportion of equity financing.

Cash Flow

WuXi AppTec exhibits solid cash flow management with a 4.68% growth in free cash flow. The operating cash flow to net income ratio of 0.72 and free cash flow to net income ratio of 0.69 indicate efficient cash conversion and strong liquidity. These metrics highlight the company's ability to generate cash from operations and sustain growth.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	44.38B	39.24B	40.34B	39.35B	22.90B	16.54B
Gross Profit	20.25B	16.28B	16.57B	14.68B	8.31B	6.28B
EBITDA	18.82B	14.54B	14.17B	12.42B	7.37B	4.51B
Net Income	14.99B	9.45B	9.61B	8.81B	5.10B	2.96B
Balance Sheet
Total Assets	94.60B	80.33B	73.67B	64.69B	55.13B	46.29B
Cash, Cash Equivalents and Short-Term Investments	33.00B	19.56B	14.56B	7.99B	8.77B	14.85B
Total Debt	9.09B	4.75B	5.45B	5.87B	4.28B	4.29B
Total Liabilities	23.13B	21.24B	18.15B	17.76B	16.37B	13.57B
Stockholders Equity	70.95B	58.63B	55.12B	46.59B	38.49B	32.49B
Cash Flow
Free Cash Flow	10.51B	8.40B	7.87B	650.34M	-2.35B	942.69M
Operating Cash Flow	15.58B	12.41B	13.39B	10.62B	4.59B	3.97B
Investing Cash Flow	-2.05B	-5.52B	-7.56B	-9.69B	-4.84B	-8.78B
Financing Cash Flow	2.42B	-3.83B	-3.94B	-1.28B	-1.72B	9.89B

WuXi AppTec Co., Ltd. Class H Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 113.60
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2359, the sentiment is Negative. The current price of 113.6 is below the 20-day moving average (MA) of 117.28, below the 50-day MA of 113.94, and above the 200-day MA of 102.11, indicating a neutral trend. The MACD of -1.84 indicates Positive momentum. The RSI at 40.20 is Neutral, neither overbought nor oversold. The STOCH value of 29.27 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2359.

WuXi AppTec Co., Ltd. Class H Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
3692	73 Outperform	HK$202.97B	12.89	16.09%	0.97%	8.68%	0.82%
2268	73 Outperform	HK$69.76B	16.64	19.62%	―	―	―
2359	69 Neutral	HK$307.02B	21.89	25.65%	1.84%	11.55%	64.46%
2269	63 Neutral	HK$145.31B	10.60	9.79%	―	16.90%	63.11%
3759	63 Neutral	HK$54.10B	26.08	10.94%	1.04%	14.50%	-19.24%
3347	62 Neutral	HK$48.24B	14.14	2.72%	0.80%	-3.81%	-34.76%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

WuXi AppTec Co., Ltd. Class H Corporate Events

WuXi AppTec Flags Strong 2025 Earnings Surge on CRDMO Growth and Investment Gains

WuXi AppTec issued a positive profit alert, indicating it expects significant year-on-year growth in both revenue and earnings for the financial year ending 31 December 2025, based on preliminary figures prepared under Chinese accounting standards. The company forecasts revenue of about RMB45.46 billion, up 15.84% from 2024, with revenue from continuing operations rising roughly 21.40%, and adjusted non-IFRS net profit attributable to shareholders increasing 41.33% to around RMB14.96 billion. Net profit after deducting non-recurring items is projected to grow 32.56% to about RMB13.24 billion, while total net profit attributable to shareholders is expected to surge 102.65% to approximately RMB19.15 billion, driven in part by investment income from the sale of a partial interest in an associate and divestiture of certain business. The company highlights that its sustained growth is underpinned by its integrated CRDMO model and ongoing efficiency gains, while cautioning shareholders and potential investors to exercise care when dealing in its securities.

The most recent analyst rating on (HK:2359) stock is a Hold with a HK$111.00 price target. To see the full list of analyst forecasts on WuXi AppTec Co., Ltd. Class H stock, see the HK:2359 Stock Forecast page.

WuXi AppTec Grants Additional H Share Awards to 24 Managers Without Diluting Shareholders

WuXi AppTec has made a further grant of 126,240 existing H shares under its 2024 H Share Award and Trust Scheme to 24 independent senior, mid-level and basic-level managers, representing about 0.0247% of its issued H shares and 0.0042% of its total share capital. The shares, which were acquired on-market by a trustee and do not involve new issuance, avoid dilution for existing shareholders, and the board, including independent non-executive directors, considers the grant to be on normal commercial terms and in the interests of the company and its shareholders, underscoring continued use of equity incentives to retain and motivate key management talent.

The most recent analyst rating on (HK:2359) stock is a Hold with a HK$111.00 price target. To see the full list of analyst forecasts on WuXi AppTec Co., Ltd. Class H stock, see the HK:2359 Stock Forecast page.

WuXi AppTec Finalizes Subsidiary Disposal, Boosting 2024 Profits

WuXi AppTec Co., Ltd. has completed the disposal of its subsidiaries, WuXi Clinical and WuXi MedKey, to Hillhouse, receiving an initial payment of RMB1.54 billion. This transaction is expected to generate a net profit of approximately RMB0.96 billion, significantly impacting the company’s financials by contributing over 10% of its net profit for the year 2024.

The most recent analyst rating on (HK:2359) stock is a Buy with a HK$114.00 price target. To see the full list of analyst forecasts on WuXi AppTec Co., Ltd. Class H stock, see the HK:2359 Stock Forecast page.